Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Reference-Cited by-同舟云学术

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Published:2016-11-15 Issue:5 Volume:57 Page:616-626
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Gibbs John P.¹²,Doshi Sameer¹,Kuchimanchi Mita¹,Grover Anita¹³,Emery Maurice G.¹,Dodds Michael G.¹⁴,Gibbs Megan A.¹³,Somaratne Ransi¹,Wasserman Scott M.¹,Blom Dirk⁵

Affiliation:

1. Amgen Inc Thousand Oaks CA, USA

2. Current affiliation: AbbVie North Chicago IL, USA

3. Current affiliation: BioMarin Pharmaceuticals Novato CA, USA

4. Current affiliation: Quantitative Solutions, a Certara Company Seattle WA, USA

5. Division of Lipidology, Department of MedicineUniversity of Cape Town Cape Town South Africa

Funder

Amgen

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology